Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT).
Puricel S, Kallinikou Z, Espinola J, Arroyo D, Goy JJ, Stauffer JC, Baeriswyl G, Smits PC, Cook S, Togni M. Puricel S, et al. Among authors: baeriswyl g. Int J Cardiol. 2016 Jan 1;202:525-31. doi: 10.1016/j.ijcard.2015.09.085. Epub 2015 Sep 26. Int J Cardiol. 2016. PMID: 26440470 Clinical Trial.
Long-term comparison of everolimus-eluting and biolimus-eluting stents.
Puricel S, Oberhänsli M, Guntern P, Lehmann S, Goy JJ, Arroyo D, Villeneuve H, Baeriswyl G, Stauffer JC, Togni M, Cook S. Puricel S, et al. Among authors: baeriswyl g. EuroIntervention. 2013 Jul;9(3):336-44. doi: 10.4244/EIJV9I3A55. EuroIntervention. 2013. PMID: 23482296 Free article.
Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
Kallinikou Z, Arroyo D, Togni M, Lehman S, Corpataux N, Cook M, Müller O, Baeriswyl G, Stauffer JC, Goy JJ, Puricel SG, Cook S. Kallinikou Z, et al. Among authors: baeriswyl g. Swiss Med Wkly. 2016 Jan 14;146:w14274. doi: 10.4414/smw.2016.14274. eCollection 2016. Swiss Med Wkly. 2016. PMID: 26766027 Free article. Clinical Trial.
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
Arroyo D, Gendre G, Schukraft S, Kallinikou Z, Müller O, Baeriswyl G, Stauffer JC, Goy JJ, Togni M, Cook S, Puricel S. Arroyo D, et al. Among authors: baeriswyl g. Int J Cardiol. 2017 Sep 15;243:121-125. doi: 10.1016/j.ijcard.2017.05.053. Epub 2017 May 12. Int J Cardiol. 2017. PMID: 28576627 Clinical Trial.
Five-year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Schukraft S, Arroyo D, Togni M, Goy JJ, Wenaweser P, Stadelmann M, Baeriswyl G, Muller O, Stauffer JC, Puricel S, Cook S. Schukraft S, et al. Among authors: baeriswyl g. Catheter Cardiovasc Interv. 2022 Feb;99(3):523-532. doi: 10.1002/ccd.29837. Epub 2021 Jun 26. Catheter Cardiovasc Interv. 2022. PMID: 34173699 Free PMC article. Clinical Trial.
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
Oberhänsli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer JC, Baeriswyl G, Goy JJ, Cook S. Oberhänsli M, et al. Among authors: baeriswyl g. Arch Cardiovasc Dis. 2012 Nov;105(11):587-92. doi: 10.1016/j.acvd.2012.06.001. Epub 2012 Oct 4. Arch Cardiovasc Dis. 2012. PMID: 23177487 Free article. Clinical Trial.
15 results